国际肿瘤学杂志

国际肿瘤学杂志 ›› 2019, Vol. 46 ›› Issue (10): 617-619.doi: 10.3760/cma.j.issn.1673-422X.2019.10.010

• 综述 • 上一篇    下一篇

CDK4/6抑制剂在激素受体阳性乳腺癌治疗中的应用 

莫秋萍1,2,陈益定1,王晓晨1,2   

  1. 1浙江大学医学院附属第二医院乳腺外科，杭州310009； 2浙江省人民医院乳腺外科,杭州310014

  • 出版日期:2019-10-08 发布日期:2019-12-22
  • 通讯作者: 王晓晨，Email: wangxiaochen@zju.edu.cn E-mail: wangxiaochen@zju.edu.cn
  • 基金资助:

    浙江省自然科学基金(LY19H160056)

Application of CDK4/6 inhibitors in the treatment of hormone receptorpositive breast cancer 

Mo Qiuping1，2, Chen Yiding1, Wang Xiaochen1，2   

  1. 1Department of Breast Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China; 2Department of Breast Surgery, Zhejiang Provincial People′s Hospital, Hangzhou 310014, China

  • Online:2019-10-08 Published:2019-12-22
  • Contact: Wang Xiaochen, Email: wangxiaochen@zju.edu.cn E-mail: wangxiaochen@zju.edu.cn
  • Supported by:

    Natural Science Foundation of Zhejiang Province of China (LY19H160056)

PDF

281

摘要：

细胞周期依赖性蛋白激酶(CDK)4/6抑制剂因可阻滞细胞增殖，成为激素受体阳性乳腺癌有效且安全的治疗选择。CDK4/6抑制剂联合内分泌治疗方案能显著改善激素受体阳性晚期乳腺癌患者的预后，尤其可改善内分泌耐药患者预后。CDK4/6抑制剂的适应证还有望拓宽到早期乳腺癌中。但CDK4/6抑制剂耐药机制仍不明确。

关键词:

乳腺肿瘤, 受体, 雌激素, 细胞周期蛋白质依赖激酶类, 治疗学

Abstract:

With roles of blocking cell proliferation, cyclindependent protein kinase (CDK) 4/6 inhibitors are  effective and safe complementary therapies for hormone receptorpositive breast cancer. CDK4/6 inhibitors combined with endocrine therapy significantly improve the prognosis of patients with advanced or metastatic breast cancer, especially those with endocrine resistance. Indications for CDK4/6 inhibitors are also expected to broaden into earlystage breast cancer. However, mechanisms of resistance of CDK4/6 inhibitors remain elusive.

Key words:

Breast neoplasms, Receptors, estrogen, Cyclindependent kinases, Therapeutics